Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Sciatic Block (SNB) Combined With a Continuous Femoral Block (CFNB) on Pain Scores After Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Unilateral total knee replacement~Exclusion Criteria:~* Contra-indication for general anesthesia~* Infection on puncture site~* Coagulation disorders~* Pre-existent neuropathies~* Allergies to local anesthetics, paracetamol, diclofenac and tramadol~* Severe dyspepsia~* Less than 50kg weigh~* Body Mass Index (BMI) greater than 40~* American Society of Anesthesiologists (ASA) Physical Status 4 or 5~* Absence of capacity to use the Visual Analog Score (VAS) scale~* Refusal to give informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous femoral nerve block (CFNB) (Type: ACTIVE_COMPARATOR): A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
- Single shot SNB plus CFNB (Type: EXPERIMENTAL): A single shot sciatic nerve block (SNB) is performed before surgery with 25ml of 0.2% ropivacaine in addition to the continuous femoral nerve block (CFNB) performed in the control group before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in Post anesthesia care unit (PACU) and maintained for 48h

Based on this trial design, predict the completion outcome and termination type (if applicable).